<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03023345</url>
  </required_header>
  <id_info>
    <org_study_id>P160301</org_study_id>
    <nct_id>NCT03023345</nct_id>
  </id_info>
  <brief_title>Trans-rectal Focal Microwave Ablation of the Index Tumor in Patients With Low-risk Prostate Cancer</brief_title>
  <acronym>FOSTINE</acronym>
  <official_title>Evaluation of the Feasibility and Tolerance of Trans-rectal Focal Microwave Ablation of the Index Tumor in Patients With Low-risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - H么pitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - H么pitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if trans-rectal microwave ablation of the index&#xD;
      tumor of patients with low-risk prostate cancer is sufficiently precise and safe, using&#xD;
      MRI-transrectal ultrasound image registration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In men with low-risk prostate cancer, European and American guidelines recommend either&#xD;
      active surveillance or whole-gland treatments, with significant induced morbidity and burden&#xD;
      on quality of life. Focal treatments of the index tumor are currently under investigation to&#xD;
      decrease morbidity while proposing active treatment.&#xD;
&#xD;
      The purpose of this study is to determine the feasibility, precision and safety of a novel&#xD;
      ablation treatment using microwaves, delivered transrectally under real-time guidance with&#xD;
      MRI-transrectal ultrasound image registration. The index tumor will be detected with prostate&#xD;
      MRI and characterized with targeted biopsies using MRI-transrectal ultrasound image&#xD;
      registration. It will then be ablated with microwaves using the same transrectal approach and&#xD;
      guidance system (KOELIS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 12, 2017</start_date>
  <completion_date type="Actual">April 23, 2019</completion_date>
  <primary_completion_date type="Actual">November 5, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete necrosis of the index tumor on prostate MRI</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Margins of necrosis around the index tumor on prostate MRI</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erectile and Ejaculatory function using the International Index Erectile Function (IIEF) self questionnaire</measure>
    <time_frame>7 days</time_frame>
    <description>to assess sexual tolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erectile and Ejaculatory function using the International Index Erectile Function (IIEF) self questionnaire</measure>
    <time_frame>1 month</time_frame>
    <description>to assess sexual tolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erectile and Ejaculatory function using the International Index Erectile Function (IIEF) self questionnaire</measure>
    <time_frame>3 months</time_frame>
    <description>to assess sexual tolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erectile and Ejaculatory function using the International Index Erectile Function (IIEF) self questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>to assess sexual tolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary symptoms using IPSS</measure>
    <time_frame>7 days</time_frame>
    <description>to assess urinary tolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary symptoms using IPSS</measure>
    <time_frame>1 month</time_frame>
    <description>to assess urinary tolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary symptoms using IPSS</measure>
    <time_frame>3 months</time_frame>
    <description>to assess urinary tolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary symptoms using IPSS</measure>
    <time_frame>6 months</time_frame>
    <description>to assess urinary tolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cancer on targeted biopsies within the treated volume</measure>
    <time_frame>6 months</time_frame>
    <description>to assess oncological efficacy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Low-Risk Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Microwave</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Microwave trans rectal focal treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microwave trans rectal focal treatment</intervention_name>
    <description>Microwave trans-rectal ablation of the prostatic index tumor using MRI-transrectal ultrasound image registration</description>
    <arm_group_label>Microwave</arm_group_label>
    <other_name>Microwave thermal ablation system called TATO (Biomedical)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged from 45 to 76 years old ;&#xD;
&#xD;
          -  Life expectancy above 10 years ;&#xD;
&#xD;
          -  Diagnosis of prostate cancer confirmed on prostate biopsies ;&#xD;
&#xD;
          -  Low risk of progression, defined with D'Amico criteria :&#xD;
&#xD;
               -  T1c or T2a stage&#xD;
&#xD;
               -  Maximum Gleason score of 3+4, including targeted biopsies corresponding to less&#xD;
                  than 50% grade 4 for the tumor&#xD;
&#xD;
               -  Prostate Specific Antigen &lt;15 ng/mL&#xD;
&#xD;
          -  Detection of the index tumor with prostate MRI, characterized with targeted biopsies&#xD;
             using MRI-transrectal ultrasound image registration ;&#xD;
&#xD;
          -  Patient accepting to be followed after the procedure using active surveillance&#xD;
             protocol standards ;&#xD;
&#xD;
          -  Patient affiliated to national health care insurance ;&#xD;
&#xD;
          -  Free consent, informed and written, dated and signed by the patient and the&#xD;
             investigator before enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical past history of prostatic surgery ;&#xD;
&#xD;
          -  Medical past history of radiotherapy or pelvic trauma ;&#xD;
&#xD;
          -  Medical past history of acute or chronic prostatitis&#xD;
&#xD;
          -  severe BPH-related urinary tract symptoms defined as an IPSS &gt;18 ;&#xD;
&#xD;
          -  Extra-capsular extension or seminal vesicle invasion on prostate MRI.&#xD;
&#xD;
          -  Tumor involvement &gt; 3 mm on systematic biopsies outside the tumor volume detected on&#xD;
             MRI.&#xD;
&#xD;
          -  Tumor largest axis &gt; 20 mm on prostate MRI ;&#xD;
&#xD;
          -  Distance of less than 5 mm between the tumor and the rectum&#xD;
&#xD;
          -  Patient unable to understand the course of the study&#xD;
&#xD;
          -  History of allergy or non-tolerance to gadolinium salts used in MRI&#xD;
&#xD;
          -  Patient with a contraindication to performing an MRI&#xD;
&#xD;
          -  Person placed under safeguard of justice&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas BARRY DELONGCHAMPS, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - H么pitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assistance Publique - H么pitaux de Paris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 13, 2017</study_first_submitted>
  <study_first_submitted_qc>January 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2017</study_first_posted>
  <last_update_submitted>July 31, 2021</last_update_submitted>
  <last_update_submitted_qc>July 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>prostate</keyword>
  <keyword>PSA</keyword>
  <keyword>biopsies</keyword>
  <keyword>microwave trans rectal focal treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

